<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="676">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05152355</url>
  </required_header>
  <id_info>
    <org_study_id>INTB011H01</org_study_id>
    <nct_id>NCT05152355</nct_id>
  </id_info>
  <brief_title>Clinical Equivalence of Budesonide HFA MDI Versus Budesonide Turbuhaler in Mild to Moderate Chinese Asthma Patients</brief_title>
  <official_title>Multi-center, Single Blind, Randomized, Parallel Study to Compare the Clinical Efficacy and Safety of Dusama (Budesonide) HFA MDI With Pulmicort (Budesonide) Turbuhaler in Mild to Moderate Chinese Asthma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intech Biopharm Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GCP ClinPlus Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Aicomer Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Key Tech</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Healthcare Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin First Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bao Gang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Inner Mongolia Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Yi Hua Hospital Management Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Shanxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shaanxi Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jining Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qingdao Municipal Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daqing Oil Field Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Jinan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Meizhou People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Meiheko Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Intech Biopharm Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the efficacy and safety of budesonide HFA&#xD;
      MDI 200 mcg 2 puffs BID versus budesonide DPI (Turbuhaler) 100 mcg 4 puffs BID in Chinese&#xD;
      mild to moderate Asthma patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 270 Chinese mild to moderate Asthma patients will be enrolled and 230 will be&#xD;
      completed in this multi-center, randomized, single blind, parallel efficacy and safety&#xD;
      comparison study of budesonide HFA MDI 200 mcg 2 puffs BID versus budesonide DPI (Turbuhaler)&#xD;
      100 mcg 4 puffs BID.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 22, 2019</start_date>
  <completion_date type="Actual">May 9, 2021</completion_date>
  <primary_completion_date type="Actual">May 9, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Single blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from base line of FEV1</measure>
    <time_frame>Week 0, 2 and 4</time_frame>
    <description>The change from base line of forced expiratory volume in one second after 4 weeks treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from base line of morning and evening PEF</measure>
    <time_frame>Week 0 and 4</time_frame>
    <description>The mean change from base line of morning and evening PEF (peak expiratory flow)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from base line of FVC</measure>
    <time_frame>Week 0 and 4</time_frame>
    <description>The changes from base line of FVC after 4 weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from base line of FEV1/FVC ratio</measure>
    <time_frame>Week 0 and 4</time_frame>
    <description>The changes from base line of FEV1/FVC ratio after 4 weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from base line of FEF25%</measure>
    <time_frame>Week 0 and 4</time_frame>
    <description>The changes from base line of FEF25% after 4 weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from base line of FEF50%</measure>
    <time_frame>Week 0 and 4</time_frame>
    <description>The changes from base line of FEF50% after 4 weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from base line of FEF75%</measure>
    <time_frame>Week 0 and 4</time_frame>
    <description>The changes from base line of FEF75% after 4 weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from base line of ACT</measure>
    <time_frame>Week 0, 2 and 4</time_frame>
    <description>The change from base line of Asthma Control Test after 4 weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily PEF variability</measure>
    <time_frame>during week 0 to 4</time_frame>
    <description>The Daily PEF variability (= (daily highest PEF-daily lowest PEF)X2/((daily highest PEF+daily lowest PEF) X 100% during the whole treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly PEF variability</measure>
    <time_frame>during week 0 to 4</time_frame>
    <description>The Weekly PEF variability (= (biweely highest PEF-biweekly lowest PEF)X2/((biweekly highest PEF+biweekly lowest PEF) X 100% during the whole treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of day time and night time symptom</measure>
    <time_frame>during week 0 to 4</time_frame>
    <description>The changes of day time and night time symptom during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects number with acute exacerbation</measure>
    <time_frame>during week 0 to 4</time_frame>
    <description>The total number of subjects with acute exacerbation during treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total amount of rescue medication, Ventolin 100 mcg inhaler, used</measure>
    <time_frame>during week 0 to 4</time_frame>
    <description>The total amount of doses of rescue medication, Ventolin 100 mcg inhaler, used during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of days without symptom</measure>
    <time_frame>during week 0 to 4</time_frame>
    <description>The percentage of days without asthma symptom during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of days without using rescue medicine</measure>
    <time_frame>during week 0 to 4</time_frame>
    <description>The percentage of days without using rescue medicine during the treatment period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">270</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Budesonide HFA MDI (Treatment A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants assigned to Experimental arm will inhaled 2 puffs of budesonide 200 mcg HFA MDI bid (am 08:00 and pm 16:00) for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide DPI (Turbuhaler) (Treatment B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants assigned to Active Comparator arm will inhaled 4 puffs of budesonide 100 mcg powder for inhalation bid (am 08:00 and pm 16:00) for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide 200 microgram/Puff, HFA MDI</intervention_name>
    <description>Participants will inhaled 2 puffs of budesonide 200 mcg HFA MDI bid (am 08:00 and pm 16:00) for 4 weeks, if necessary rescue Ventolin (Salbutamol Sulfate) 100 mcg 2 puffs could be used with maximum daily dose of 8 puffs.</description>
    <arm_group_label>Budesonide HFA MDI (Treatment A)</arm_group_label>
    <other_name>Duasma 200 mcg inhaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide 100 microgram/Actuation Powder for Inhalation</intervention_name>
    <description>Participants will inhaled 4 puffs of budesonide 100 mcg DPI bid (am 08:00 and pm 16:00) for 4 weeks, if necessary rescue Ventolin (Salbutamol Sulfate) 100 mcg 2 puffs could be used with maximum daily dose of 8 puffs.</description>
    <arm_group_label>Budesonide DPI (Turbuhaler) (Treatment B)</arm_group_label>
    <other_name>Pulmicort 100 mcg Turbuhaler</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 to 70 years old and diagnosed as Asthma in clinics&#xD;
&#xD;
          -  Diagnosed as Asthma according to the 2016 Asthma guidance of Chinese Thoracic Society,&#xD;
             and without administer corticosteroids within three months, either new or old patients&#xD;
&#xD;
          -  FEV1 predicted ≧ 60%&#xD;
&#xD;
          -  Patients is willing to participate the study and signed the Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to budesonide or salbutamol&#xD;
&#xD;
          -  Infections of Respiratory tract, nasal-sinus and ear within 4 weeks before enrollment&#xD;
&#xD;
          -  Severe nasal allergy and need the treatment of corticostreoids and histamines.&#xD;
&#xD;
          -  Severe cardiovascular disease history&#xD;
&#xD;
          -  Has used leukotriene receptor antagonist (Montelukast, Pranlukast, Zafirlukast etc.)&#xD;
             within 2 weeks before enrollment&#xD;
&#xD;
          -  Severe cognition or mental disorder and can not cooperation with the treatment&#xD;
&#xD;
          -  Significant liver dysfunction, AST, ALT &gt; 3 X normal upper limits, CR &gt; 1.5 X normal&#xD;
             upper limits&#xD;
&#xD;
          -  Patients with uncontrolled diabetes or fasting blood glucose &gt; 10 mmol/L&#xD;
&#xD;
          -  Patients currently receiving beta-antagonists or beta-agonists treatment (including&#xD;
             eye drops)&#xD;
&#xD;
          -  Patients who has contraindications to beta2-agonists&#xD;
&#xD;
          -  Patients who has participated others drug's clinical study within three months&#xD;
&#xD;
          -  Female patients who are pregnant or lactation or prepare to pregnant&#xD;
&#xD;
          -  Any conditions which the investigators considered not suitable to enrolled&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Hsiu Wu, MBA</last_name>
    <role>Study Chair</role>
    <affiliation>Intech Biopharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Jinan University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510650</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meizhou People's Hospital</name>
      <address>
        <city>Meizhou</city>
        <state>Guangdong</state>
        <zip>514031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Shijia Zhuang</city>
        <state>He Bei Sheng</state>
        <zip>050017</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daqing Oil Field Hospital</name>
      <address>
        <city>Daqing</city>
        <state>Heilongjiang</state>
        <zip>163411</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bao Gang Hospital</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <zip>014000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Inner Mongolia Medical University</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia</state>
        <zip>010100</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meiheko Central Hospital</name>
      <address>
        <city>Tonghua</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shan XI Sheng</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanxi Provincial People's Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shan XI Sheng</state>
        <zip>030012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jining Medical University</name>
      <address>
        <city>Jining</city>
        <state>Shandon</state>
        <zip>272000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QingDao Municipal Hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandon</state>
        <zip>266011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin First Central Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300393</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>November 28, 2021</last_update_submitted>
  <last_update_submitted_qc>November 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>budesonide</keyword>
  <keyword>MDI</keyword>
  <keyword>DPI</keyword>
  <keyword>China</keyword>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

